PulseSight Therapeutics is a clinical-stage biotech company developing disruptive novel non-viral vectorized gene therapies dedicated to ophthalmology, with a focus on age related macular degeneration (AMD) Including late-stage dry AMD/Geographic atrophy (GA) and wet AMD.
Latest news
October 14, 2025
Peer Reviewed Publication Provides Evidence for Iron Dysregulation as a Driver of Dry AMD/GA and the Potential of Transferrin to Restore Iron Balance, Reinforcing PulseSight’s Therapeutic Strategy for PST-611
September 4, 2025
PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025
July 7, 2025
First patient dosed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy